← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
CoreWeave, Inc.: Revenue grew 167.9% to $5.131B from $1.915B. Net loss widened to $1.167B from $863M. Free cash flow outflow widened to $7.251B from $5.953B. Operating margin contracted 1782 bps to -0.90%. CoreWeave, Inc.'s annual comparison also shows free cash flow declined despite revenue growth; stock compensation grew faster than revenue; the manipulation screen is flagged and should be investigated as a warning rather than treated as proof; the balance-sheet screen falls in the distress range and requires business-model context.
The read at a glance✓ Audited against SEC data
- Growth — Revenue grew 167.9% to $5.131B from $1.915BOK
- Profitability — Net loss widened to $1.167B from $863MWatch
- Cash flow — Free cash flow outflow widened to $7.251B from $5.953BWatch
- Margins — Operating margin contracted 1782 bps to -0.90%Watch
- Accounting — Flagged statistical warning; not proofWatch
- Insiders — 0 purchases and 162 salesWatch
Business
Curiosity is a driving force that allows us to explore ideas and innovations that push boundaries, challenge the status quo, and better serve our customers. • Act Like an Owner .
Latest filings
- 10-Q · Quarterly report2026-08-12
- 8-K · Company announcement2026-08-11
- 8-K · Company announcement2026-08-10
- 8-K · Company announcement2026-06-18
- 8-K · Company announcement2026-06-11
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about CoreWeave, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.